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ABSTRACT 
Introduction. The management of large burn victims has significantly improved in the last 
decades. Specifically autologous cultured keratinocytes (CEA) overcame the problem of 
limited donor sites in severely burned patients. Several studies testing CEA’s in their burn 
centers give mixed results on the general outcomes of burn patients.  
Methods. A review of publications with a minimum of 15 patients per study using CEA for 
the management of severe burn injury from 1989 until 2011 were recruited by using an 
online database including Medline, Pub Med and the archives of the medical library of the 
CHUV in Lausanne. 
Results. 18 studies with a total of 977 patients were included into this review. Most of the 
studies did not specify if CEA’s were grafted alone or in combination with split thickness skin 
grafts (STSG) although most of the patients seemed to have received both methodologies in 
reviewed studies. The mean TBSA per study ranged from 33% to 78% in patients that were 
grafted with CEA’s. Here no common minimum TBSA making a patient eligible for CEA 
grafting could be found. The definition of the “take rate” is not standardized and varied 
largely from 26% to 73%. Mortality and hospitalization time could not be shown to correlate 
with CEA use in all of the studies. As late complications, some authors described the fragility 
of the CEA regenerated skin.  
Conclusion. Since the healing of large burn victims demands for a variety of different surgical 
and non-surgical treatment strategies and the final outcome mainly depends on the burned 
surface as well as the general health condition of the patient, no definitive conclusion could 
be drawn from the use of CEA’s of reviewed studies. From our own experience, we know 
that selected patients significantly profit from CEA grafts although cost efficiency or the 
reduction of mortality cannot be demonstrated on this particular cases. 
Key words. Cultured epithelial autografts, burn wounds, take rate, TBSA, split-thickness skin 
grafts. 
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INTRODUCTION 
Over the last decades, the management of severe burn wounds has been significantly 
improved. Especially intensive care medicine including the resuscitation standards, nutrition 
and the management of wound infection that increased the survival of patients with 
extensive burns [1] urged for the development of novel methods to cover large wounds. The 
first Xenograft was based on a bovine tendon. Derived collagen matrix was introduced in 
1980 by Yannas et al [2] to regenerate their dermal layer. Later, pig and cadaveric dermis 
were introduced for immediate but temporally wound cover. The wound cover with 
xenografts initially showed good results of integration in early stages of immunosuppression 
in large burn victims but were complicated by immediate to late rejections of the xenograft 
[3]. Immunosuppressive therapies were limited by the risk of a neutropenic state in these 
patients [4].  
The practice of early excision of nonviable tissue followed by immediate skin grafting has 
resulted in a further improvement in survival [5]. Split thickness largely meshed skin grafting 
remains the gold standard to cover large wounds in burn victims. Severely burned patients 
presenting deep burns over 50% of their total body surface area (TBSA) lack healthy skin for 
skin grafting. One of the major innovations overcoming the limitation covering large wounds 
with only limited healthy donor sites in extensively burned patients was the innovation of 
autologous keratinocyte culture [9]. 
The discovery and application of cultured epithelial autografts (CEA) was invented by 
Rheinwald and Green [6] in the early 1980s. CEA’s resulted in great interest for the 
treatment of severely burned patients. The CEAs are obtained by a small biopsy of healthy 
skin of the patient and in the laboratory extracted keratinocytes are then put into culture. 
Within a delay of 2 to 3 weeks, expansion sheets of keratinocytes are obtained and are 
available to be grafted on the burn wounds. Despite initial optimism, high cost, complex 
application and sensitivity to infections were criticized later [7]. However, many burn centers 
in developed countries can offer CEAs for the treatment of severely burned patients and are 
the only method to achieve wound coverage in large burn victims [8]. Even though the time 
to obtain keratinocytes sheets has been significantly reduced to 2-3 weeks throughout the 
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last decades, the gold standard for burn wounds cover remains the split-thickness skin grafts 
(STSG) [28], [29], [30]. Since published data on clinical results of CEA treatment are largely 
miscellaneous, we here reviewed the literature of the last decade of burn centers presenting 
their results on this subject. 
 
MATERIAL AND METHODS 
Using a databank research in refer to cultured epithelial autograft and keratinocyte 
transplantation on Medline, Pub Med and the archives of the medical library of the CHUV in 
Lausanne, we included studies between 1989 and 2011, that have been using CEA’s only or 
in association with STSG’s for burn wounds coverage in large burn victims. Included studies 
presented at least a number of 15 patients in a single or multi center study and were either 
prospective or retrospective studies. Publications were reviewed emphasizing on: 
- Number of patients  
- Sex  
- Age 
- TBSA % of burn 
- Standard burn wound care 
- Definite wound coverage (CEA and skin graft only or in combination) 
- CEA culture 
- Take rate 
- Time of hospitalization  
- Mortality 
Results were compiled in a table and data were analyzed extensively in each study included. 
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RESULTS  
Included studies. 18 studies have been included in this review. 15 of them were single-
center studies whereas 3 were multi-center studies. The majority of the studies were 
retrospectives and there was only one prospective study.   
Patient population. The total number of patients in all the studies included is 977 patients 
with an average of 54.22 patients per study. The smallest collective was 15 patients and the 
tallest collective was 240 patients. The mean age of the patients was 28 years (+/- 9.3 years) 
(Table 1). The cut-off between pediatric and adult age was not found in every study but was 
at 15 years in the Carsin & al study [11]. Studies that provided data about the sex of the 
patients all included more men than women into their studies. The lowest ratio of women 
was 8% in the Gómez & al study whereas the highest ratio was 43.75% in the Foyatier & al 
study (Table 1).   
TBSA. Only 14 studies provided the TBSA% and 11 studies the TBSA% of full-thickness burn 
(Table 1). The mean TBSA% of included patients was 48% (+/-23%) whereas the mean TBSA% 
of full-thickness burn was 38.79% (+/-20.17) (Table 1). 
Inhalation injuries. Studies, which provided the information if an inhalation injury was 
present or not showed a higher mortality in patients with compared to patients without an 
inhalation injury. To diagnose the inhalation injury bronchoscopy was commonly performed 
at the time of admission [11], [12], [16]. 
Standard burn wound care. On the day of the admission of the burn victim into the burn 
center, authors commonly evaluated the TBSA of burn in the shower and further diagnostics 
were conducted to detect inhalation or other injuries. Showers were performed commonly 
every day or at least every 72 hours. Wound dressings mainly included antiseptic topical 
silver sulfadiazine containing creams such as for example Flammacérium® [11].  
Authors followed the gold standard of early excision of the burn wounds as the patient 
general conditions would allow, usually during the first 48 hours to days after the injury [13]. 
The maximum excision procedure cut-off varied among studies and was maximally limited at 
30% in the Cirodde study [12]. Excised areas were temporally covered with allografts such as 
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Alloderm® [13], which is an acellular collagen matrix made of cadaveric skin, Integra® [12]  
[16], which is a bilayer silicone and porous matrix or porcine skin. If CEA was planned to 
cover wounds, a small biopsy of full-thickness healthy skin of a few square centimeters were 
taken at the site of unburned skin or preferably in the groin or axillary regions of the patient 
[13] and were sent to laboratories for culturing of the keratinocytes. 
 
Definitive wound coverage  
STSG. STSG were preferably taken from the anterior surfaces of the body such as the trunk, 
anterior surfaces of the lower limbs and of the arms, which are less exposed to trauma and 
pressure in supine position [12]. Surgical techniques included all kinds of air or electric 
driven dermatomes. STSGs were commonly meshed with a 1:2 to 1:6 ratio.  
CEA culture. Studies mostly provided only a brief protocol for CEA culturing. The protocols 
included small biopsies of full-thickness skin of a few square centimeters unburned skin [12] 
[13] and sent to laboratories for culturing of the keratinocytes. Each laboratory had their 
own protocol, but consisted usually in a first step of many washes to remove contaminants. 
The samples were then placed with trypsin and EDTA to isolate the keratinocytes. 
Trypsinization was ended with the use of a trypsin inhibitor and the products were seeded 
into a fetal bovine serum (FBS)-free and cultured at a 37°C temperature in a 5% to 10% CO₂ 
incubator until the keratinocytes grew to confluence [13], [15]. Once ready the cultured 
keratinocytes were sent back to burn centers prepared as sheets in Petri dishes consisting of 
stratified layers of keratinocytes fixed on a petrolatum gauze [12]. Culturing of the CEAs 
ranged from two to four weeks depending on the study. 
STSG & CEA. Most authors used wide meshed STSG in combination with CEA, authors did 
not specify which ratio indicated a switch from only STSG to STSG plus CEA. The exception 
was the Carsin & al study [11] where they used the cut-offs of 70% of TBSA and 60% of TBSA 
of full-thickness as these represented their general institutional target indication for CEA 
application. Authors state that CEA allowed a much wider mesh of STSG than when STSG 
was used alone [14]. Authors did not mention a maximum cut-off to mesh STSG in 
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combination with CEA. Most of the publications used STSG in association with CEA when the 
TBSA of full-thickness burns were over 50% [11], [12], [16]. In the study by Wood et al [14] 
only 3 patients out of the 62 patients received CEA sheets alone, whereas the 59 other 
patients were grafted with a combination of STSG and CEA. STSG were preferred for the 
back regions of the body as they could prepare the wounds to receive CEA a few weeks later 
to help reepithelialization, indeed CEA alone in those regions are very weak and sensitive to 
any friction. 
 Take rate. Most authors report a take rate over 30% without details about if the wound was 
covered with CEA alone or in combination with STSG. The take rates globally ranged from 
26% to 73% with a mean value of 47.7% (+/-26.8%) (Table 1). 
The correlation of take rate and other factors were not described in all studies. Carsin & al 
reported that they could not find any statistical relationship between take rate and TBSA as 
well as they could not show a significant relationship between the take and the timing of 
CEA culture, but they significantly showed that the only factor associated with a better take 
rate was a younger age (p < 0.04)  [11].  
Time of hospitalization. The mean time of hospitalization was 63.9 days (+/- 34.2 days). 
Hospitalization times ranged from 43 days [15] to 132 and 275 days [16], [17]. Wood & al 
found that only the number of operative procedures correlated with the hospitalization time 
(p < 0.001) [14]. 
Mortality. The overall mortality rate reported in the reviewed studies was 14% (+/- 5.13%). 
The highest mortality rate was reported by older studies conducted in 1980’s and 1990’s 
with mortality rates ranging from 10-20% [20] (Table 1), while the lower rates were reported 
in more recent studies (4-16%) [5], [11], [12], [16]. 
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Investigators Burn unit 
N° of 
patients 
Sex 
(M/F) 
Age 
(years) 
TBSA of 
burns (%) 
TBSA of 
3° burns 
(%) 
Graft Take rate (%) 
Hospitalization 
time (days) 
Mortality (%) 
Carsin & al (1999) Clamart 
(France) 
30 19/11  78±10 65±16 CEA 69±23 114±30 10 
Wood & al (2006) Perth (Australia) 62   62.3±14.8  CEA  95±70 16.1 
Gómez & al (2010) 5 burn units of 
Spain 
25 23/2 29±11 74±17 61±19 ABCS 49±30 132±69 4 
Yim & al (2011) Seoul (Republic 
of Korea) 
29 26/3 42 (30-
49) 
55 (44-
60) 
40 (30-
46.5) 
CEA 96 week 2, 
100 week 4 
  
Cirodde & al (2011) Clamart 
(France) 
63 45/18 29 (17-
41.5) 
81±10 69±14 CEA 26.1±15.5 114 (93-149) 16 
Sood & al (2010) Indianapolis 
(USA) 
88  29.4 
(0.5-73) 
58.5 (28-
98) 
51.2 (0-
94) 
CEA 72.7  9 
Archer & al (1998) Cincinnati (USA) 100 71/29  56.9 50.5 CEA 
(n=18) 
 58.3 22 
Clugston & al (1991) Vancouver 
(Canada) 
18 16/2  49 38 CEA 33.8   
De Luca & al (1989) Genoa (Italy) 40   53.1 37.75 CEA 37 43.1  
Donati & al (1992) Milano (Italy) 26   33 28.91 CEA 32.5   
Foyatier & al (1989) Lyon (France) 16 9/7 34 (6-
88) 
66 (30-
92) 
 CEA 9 pat>50, 3 
pat<50, 4 
pat=0 
 18.75 
Mühlbauer (1995) München 
(Germany) 
141     CEA 39.5   
Munster & al (1996) Baltimore (USA) 22 19/3 31.8±3.1 71.8±2.5 43.7±4.8 CEA  96.4±15.2 14 
Odessey & al (1992) Cambridge 
(USA) 
240  28   CEA 60   
Rue & al (1993) Birmigham 
(USA) 
16  29.7 
(10-56) 
68.2 (42-
85) 
 CEA 46.7 132 (50-275) 12.5 
Still & al (1994) Augusta (USA) 15     CEA 71.5  13.33 
Tamisani & al (1992) Genoa (Italy) 17     CEA 
(n=7) 
57.1   
Williamson & al (1995) Vancouver 
(Canada) 
28 23/5 35.3 
(13-81) 
52.2 (15-
84) 
42.4 
(12-80) 
CEA 26.9 90.4  
 
Table 1: Summary of reviewed papers. 
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DISCUSSION 
The management of extensive burn victims is a complex combination of operative and non 
operative treatment approaches. The development in intensive care and the concept of 
early debridement and skin grafting significantly increased the survival or extensive burn 
[30]. This manuscript particularly reviews the outcome of studies using CEA that were 
published in the last 11 years. In summary, we found that published studies presenting the 
outcome of burn patients treated with CEA lack of standardized method and detailed but 
essential information as TBSA, comorbidities and wound coverage. As former metaanalysis 
on clinical results of the use of CEA no conclusion concerning the effectivness of patient 
hospitalization, take rate or mortality could be made [7], [19].  
The discovery of CEA has evolved from a revolutionary technology to a criticized method 
because of high costs, complex application and sensitivity to infections [7]. The question of 
the indications for the use of CEA is doubtless the main question all authors wanted to 
answer in their papers. Sood & al conclude that CEA should strongly be used in the 
management of patients with burn wounds over 50% TBSA and with patients with limited 
donor site availability [5].  
First evaluation of the CEA coverage was evaluated at the first dressing change after skin 
coverage that was usually performed after 6 to 14 days [11], [12], [13], [16], [23]. Carsin & al 
report that the evaluation of graft take was complicated by the tendency of large areas that 
showed a patchy pattern of developed epidermis and open wounds [11].  
Studies showed a large range of TBSA’s and take rates from 26% to 73%. Only Odessey et al 
[22] gave detailed description on how they calculated the take rate. The take rate was 
defined as 1-(area requiring regrafting/area grafted with CEA)x100%. Other authors usually 
defined areas of take as the areas that did not have the need for a regraftment at the end of 
the treatments [11]. 
Different parameters were discussed to correlate with take rates. Authors commonly 
described a lower take rate when patients presented an inhalation injury, but unlikely the 
Carsin & al study showed the opposite [11]. Sood & al [5] assess alongside with De Luca & al 
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[15] that the main causes of graft failure were bleeding and infection. Two main elements 
seem to have an important contribution to the take rate of CEA, first the prevention of 
infection [11] with the use of topical antibiotics, and second, which is also considered as a 
key component, the early excision of all the burn wounds areas [5], [22], [23] followed by 
the placement of Alloderm® or Integra® on the wound beds and eventually the placement of 
CEA on the partially excised allodermis structure. This good evolution with this protocol is 
explained by the ability of allografts to form a biologic barrier and the promotion of the 
vascularization on the wound granulation tissue [22]. This assessment also appear in the 
Donati & al study [24] where they compared two groups of patients, one of them being 
treated with an old protocol consisting in spontaneous debridement and achieving a take 
rate of 25.8% and a second group with a protocol consisting in immediate excision and 
temporary cover by allografts and or other skin substitutes and achieving a significantly 
higher take rate of 37.4%. The study from Odessey [22] also compared the average final take 
of CEA between a group that undergone early excision (<10 days after burn injury) and had a 
final take of 78%. The group that underwent late excision had a 40% final take rate. Early 
excision seemed to prevent from wound infection as 13% of the wounds that were excised 
early developed signs of infection compared to a 48% rate of infection in wounds that 
underwent late excision [22]. 
The Carsin & al study [11] statistically showed that a good initial take rate was only 
significantly associated with a younger age (p < 0.04), even if they had strong co-morbidities 
such as inhalation injuries. The explanation for this assessment seems to be that the more 
traumatized patients are also the youngest. Donati & al [24] also observed that patients over 
65 years had a systematic lower take rate comparing to younger patients, and explained it 
by the significantly longer laboratory phase before complete confluence and stratification of 
the CEA sheets. 
In the Cirodde & al study [12], the take rate is not provided as they believed that the 
percentage of TBSA permanently covered with CEA at the time of discharge from the burn 
unit was preferable than the percentage of CEA that actually was grafted. In their series, the 
area grafted with CEA represented 26.1 ± 15.5% TBSA.   
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The mean time of hospitalization was 63.9 days with a great range since depending largely 
on the initial TBSA. Carsin & al study [11] stated 1.5 days hospitalization per percent of TBSA 
burned. Wood & al [14] found that the most significant factor influencing hospitalization 
time was the number of surgical procedures (p <0.001). 
Wood & al [14] showed that the risk of death was correlated to an older age, male gender, 
increased percentage of TBSA wound, and with initial intubation. The risk was by cons 
decreased with each additional day of hospitalization. In most of the articles, the principal 
causes of death were infections and multiple organ failure (MOF). The most common 
cultures that grew on the infection sites were Pseudomonas, Candida and Staphylococcus 
aureus [6], [11], [12], [23]. Munster & al, as the only prospective study in this review was 
also the only showing a reduction of the mortality with the use of CEA [25]. The patient 
collective was split into one group who received CEA and another group with controls. Initial 
financial limitations allowed this prospective study design. The study permitted to show a 
reduction of mortality from 48% in the control group to 14% in the CEA group (p <0.007).  
Complications of CEA use were commonly separated between early and late complications. 
The early complications were mainly blistering and shearing. Indeed the Foyatier & al study 
[18] assess that one of the primordial issue is the adherence of the CEA to the conjunctive 
tissue underneath and that even if all the components of the basement membrane are 
present at the 8th day after grafting, many month are necessary for the dermo-epidermal 
junction to maturate. This could explain early fragility of grafts until final maturation. For 
their, late complications were mostly delayed CEA loss and scar contractures [6].  
The disadvantages shown in many studies were more or less the same, but as shown in the 
critical review of the literature from Wood & al [7] those were mainly the time necessary to 
culture CEA sheets, the reliability of take rate, the vulnerability of grafts, the long-term 
durability and the cost implications of CEA therapy. Concerning the cost of CEA, Carsin & al 
[11] concluded that since this treatment option is a life-saving technology that is necessary 
only in a small patient collective per year, the cost to society is acceptable. 
The main advantage on CEA is the possibility to cover large burn victims, even if no 
advantage in hospitalization time or mortality could be demonstrated yet. One of the 
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advantages of CEA may be the reduction of the hypergranulation of wounds that is seen in 
largely meshed STSG by inhibiting connective tissue growth by keratinocyte cover [20]. In 
the Clugston & al study [23] they conclude and emphasize on the fact that CEA should be 
used and considered as an adjunct and not as an alternative to the conventional STSG 
coverage. 
 
Conclusion 
Cultured epithelial cells are a mile stone in the treatment of large burn victims. Since a 
complex treatment of large burn victims is life saving, most of the studies combine various 
surgical approaches in a non randomized manner, which makes the conclusion of 
effectiveness of CEA’s difficult. No reduction of hospital stay, number of needed operations 
or mortality, except one, could be shown with the use of CEA. Further well designed studies 
are important to better understand the ideal application, indication and effectiveness of CEA 
treatment in large burn victims. 
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